Cancer combo trial halted early after enrolling only 5 patients
NCT ID NCT05949632
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new drug (INCB099280) combined with a standard cancer drug (axitinib) in adults with advanced solid tumors that had stopped responding to other treatments. The main goals were to check safety and see if the combination could shrink tumors. The trial was terminated early after enrolling only 5 people in the UK and EU.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Addenbrookes Hospital
Cambridge, CB2 0QQ, United Kingdom
-
Beatson West of Scotland Cancer Centrewester
Glasgow, G12 0YN, United Kingdom
-
Guys Hospital
London, SE1 9RT, United Kingdom
-
St Bartholomew'S Hospital
London, EC1A 7BE, United Kingdom
-
The Royal Marsden
London, SW3 6JJ, United Kingdom
-
The Royal Marsden Nhs Foundation Trust - Sutton
Sutton, SM2 5PT, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your own immune cells beat advanced cancer?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a pill outsmart Tumors' defenses?
- Can a new immune drug outsmart Hard-to-Treat tumors?
- Can a protein calm the immune System's overreaction to cancer treatment?